More specifically, increased BCAT1 activity/expression found in AML patients (with isocitrate dehydrogenase 1 (IDH1) and TET2 wild-type (wt) status) determines a reduction in α-KG levels due to the transfer of nitrogen from BCAAs to α-KG, resulting in a loss of TET and JHDM activity. This evidence concerns the gene IDH1 and acute myeloid leukemia.